Signal Transduction Pathways (MAPKs, NF-κB, and C/EBP) Regulating COX-2 Expression in Nasal Fibroblasts from Asthma Patients with Aspirin Intolerance
Overview
Authors
Affiliations
Background: Recent studies have revealed that cyclooxygenase-2 (COX-2) expression is down-regulated in aspirin-induced asthma (AIA). Various signal pathways (MAPKs, NF-κB and C/EBP) are involved in COX-2 regulation.
Objective: To investigate the regulation of COX-2 expression through MAP-kinase pathway activation and nuclear factor translocation in aspirin-induced asthma (AIA).
Methods: Fibroblasts were isolated from specimens of nasal mucosa (NM, N = 5) and nasal polyps (NP, N = 5). After IL-1β (1 ng/ml) incubation, COX-2 and phosphorylated forms of ERK, JNK and p38 MAPK were measured by Western blot. MAPK's role in IL-1β-induced COX-2 expression was assessed by treating cells with ERK (PD98059), JNK (SP600125) and p38 MAPK (SB203580) inhibitors (0.1-10 µM) prior to IL-1β exposure. NF-κB and C/EBP nuclear translocation was measured by Western blot and TransAM® after IL-1β (10 ng/ml) exposure.
Results: No differences were observed in the MAPK phosphorylation time-course between NM and NP-AIA fibroblasts. The p38 MAPK inhibitor at 10 µM significantly reduced IL-1β-induced COX-2 expression in NM fibroblasts (85%). In NP-AIA fibroblasts the COX-2 inhibition (65%) at 1 and 10 µM was not statistically significant compared to non-treated cells. ERK and JNK inhibitors had no significant effect in either the NM or NP-AIA cultures. The effect of IL-1β on NF-κB and C/EBP subunits' nuclear translocation was similar between NM and NP-AIA fibroblasts.
Conclusions: These results suggest that p38 MAPK is the only MAPK involved in IL-1β-induced COX-2 expression. NM and NP-AIA fibroblasts have similar MAPK phosphorylation dynamics and nuclear factor translocation (NF-κB and C/EBP). COX-2 downregulation observed in AIA patients appears not to be caused by differences in MAPK dynamics or transcription factor translocation.
Arasa J, Terencio M, Andres R, Marin-Castejon A, Valcuende-Cavero F, Paya M Front Immunol. 2019; 10:536.
PMID: 30984165 PMC: 6448046. DOI: 10.3389/fimmu.2019.00536.
Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma.
Liu M, Zhang J, Liu C Exp Ther Med. 2018; 15(1):539-547.
PMID: 29375702 PMC: 5763744. DOI: 10.3892/etm.2017.5376.
Rozsasi A, Heinemann A, Keck T Allergy Rhinol (Providence). 2017; 7(3):158-163.
PMID: 28107149 PMC: 5244273. DOI: 10.2500/ar.2016.7.0172.
Sphingolipids and antimicrobial peptides: function and roles in atopic dermatitis.
Park K, Lee S, Lee Y Biomol Ther (Seoul). 2013; 21(4):251-7.
PMID: 24244808 PMC: 3819896. DOI: 10.4062/biomolther.2013.058.